Weekly risperidone achieves similar drug levels as daily dose in phase 3 trial

An investigational, weekly oral dose of risperidone for schizophrenia achieved drug levels comparable to daily Risperdal in a phase 3 study involving Lynx, a long-acting drug delivery platform developed by Lyndra Therapeutics.
The positive results show that Lynx “may provide a medication option that significantly reduces dosing frequency,” Richard Scranton, MD, MPH, chief medical officer and president of global development at Lyndra, said in a company press release. “For people who rely on risperidone as part of their treatment regimen, oral weekly risperidone could vastly

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart